Veto Process
No veto information available
JINXPRO NOURA
| Player | ACS | K/D/A | ADR | KAST | FK/FD | HS% |
|---|---|---|---|---|---|---|
| meng | 340 | 36 / 16 / 19 | 234 | 97% | 5 - 2 | 21% |
| LAYKEN | 229 | 27 / 16 / 7 | 131 | 87% | 8 - 4 | 18% |
| sbubu | 187 | 24 / 14 / 10 | 116 | 83% | 4 - 0 | 23% |
| metawiN | 216 | 22 / 14 / 19 | 153 | 93% | 3 - 1 | 31% |
| Liery | 206 | 12 / 8 / 3 | 119 | 80% | 1 - 1 | 28% |
| Xalvanerva | 253 | 16 / 5 / 2 | 162 | 87% | 0 - 1 | 27% |
| Player | ACS | K/D/A | ADR | KAST | FK/FD | HS% |
|---|---|---|---|---|---|---|
| meng | 340 | 36 / 16 / 19 | 234 | 97% | 5 - 2 | 21% |
| LAYKEN | 229 | 27 / 16 / 7 | 131 | 87% | 8 - 4 | 18% |
| sbubu | 187 | 24 / 14 / 10 | 116 | 83% | 4 - 0 | 23% |
| metawiN | 216 | 22 / 14 / 19 | 153 | 93% | 3 - 1 | 31% |
| Liery | 206 | 12 / 8 / 3 | 119 | 80% | 1 - 1 | 28% |
| Xalvanerva | 253 | 16 / 5 / 2 | 162 | 87% | 0 - 1 | 27% |
RG Vipers
JINXPRO NOURA
JINXPRO NOURA
| Agent | Player | ACS | K/D/A | ADR | KAST | FK/FD | HS% |
|---|---|---|---|---|---|---|---|
|
meng | 343 | 18 / 9 / 8 | 232 | 93% | 2 - 1 | 28% |
|
Xalvanerva | 253 | 16 / 5 / 2 | 162 | 87% | 0 - 1 | 27% |
|
metawiN | 230 | 12 / 6 / 9 | 154 | 93% | 1 - 0 | 30% |
|
sbubu | 221 | 14 / 8 / 3 | 142 | 93% | 3 - 0 | 29% |
|
LAYKEN | 139 | 8 / 8 / 2 | 83 | 80% | 3 - 4 | 16% |
| Agent | Player | ACS | K/D/A | ADR | KAST | FK/FD | HS% |
|---|---|---|---|---|---|---|---|
|
meng | 343 | 18 / 9 / 8 | 232 | 93% | 2 - 1 | 28% |
|
Xalvanerva | 253 | 16 / 5 / 2 | 162 | 87% | 0 - 1 | 27% |
|
metawiN | 230 | 12 / 6 / 9 | 154 | 93% | 1 - 0 | 30% |
|
sbubu | 221 | 14 / 8 / 3 | 142 | 93% | 3 - 0 | 29% |
|
LAYKEN | 139 | 8 / 8 / 2 | 83 | 80% | 3 - 4 | 16% |